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MObjectives: Modified ultrafiltration (MUF) has been shown to decrease the postcardiac surgery inflammatory
response and to improve respiratory function and cardiac performance in pediatric patients; however, this
approach has not been well established in adults. The present study hypothesized that MUF could decrease
the postsurgical inflammatory response, leading to improved respiratory and cardiac function in adults
undergoing coronary artery bypass grafting.
Methods: Sixty patients undergoing coronary artery bypass grafting were randomized to the MUF or control
group (n¼ 30 each). MUF was performed for 15 minutes at the end of bypass. The following data were recorded
at the beginning of anesthesia, end of bypass, end of experimental treatment, and 24 and 48 hours after surgery:
alveolar-arterial oxygen gradient, red blood cell units transfused, chest tube drainage, hemodynamic parameters,
and cytokine levels (interleukin-6, P-selectin, intercellular adhesion molecule, and soluble tumor necrosis factor
receptor).
Results: The MUF group displayed less chest tube drainage than the control group after 48 hours (598  123
mL vs 848.0  455 mL; P ¼ .04) and less red blood cell transfusions (0.6  0.6 units/patient vs 1.6  1.1
units/patient; P ¼ .03). Hematocrit level was higher in the MUF group than in the control group at the end of
bypass (37.8%  1.1% vs 34.1%  1.1%; P<.05), but the levels were comparable at 48 hours. Similar
values for interleukin-6 and P-selectin were observed at all stages. Plasma levels of intercellular adhesion
molecule were higher in the MUF group than in the control group, particularly in the first sampling after
experimental treatment (P ¼ .01). Plasma levels of soluble tumor necrosis factor receptor were higher in
the MUF group than in the control group at 48 hours. Hemodynamic and oxygen transport parameters
were similar in both groups throughout the observation period. There were no differences in other clinical
outcomes.
Conclusions: Use of MUF was associated with increased inflammatory response, reduced blood loss, and
less blood transfusions in adults undergoing coronary artery bypass grafting. (J Thorac Cardiovasc Surg
2012;144:663-70)Despite advances in surgical techniques and technology and
understanding of the pathophysiology of cardiac disease,
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The Journal of Thoracic and Cato postoperative bleeding, pulmonary dysfunction, and
increased mortality and morbidity. Several strategies
have been described to minimize this response.1,2 In this
context, modified ultrafiltration (MUF) has been shown
to attenuate the inflammatory response, bleeding, and
pulmonary dysfunction in children undergoing congenital
heart surgery.3,4 From a mechanistic standpoint, MUF is
associated with removal of several inflammatory mediators
generated during CPB.5 However, in contrast with the
well-documented effects in children, use ofMUF in the adult
population has garnered mixed results.6
In some pathologic states, including acute myocardial in-
farction or reperfusion during CPB, the plasma accumulates
various stimuli that are capable of activating polymorpho-
nuclear neutrophils (PMNs) and endothelial cells.7 Acti-
vated cells may shed their adhesion molecules into the
circulating blood, where they can affect the immunologic
response. Plasma levels of soluble adhesion moleculesrdiovascular Surgery c Volume 144, Number 3 663
Abbreviations and Acronyms
A-a ¼ alveolar-arterial
A-aDO2 ¼ alveolar-arterial oxygen gradient
CABG ¼ coronary artery bypass grafting
CPB ¼ cardiopulmonary bypass
DO2 ¼ oxygen delivery
ICAM ¼ intracellular adhesion molecule
ICU ¼ intensive care unit
IL ¼ interleukin
INR ¼ international normalized ratio
MUF ¼ modified ultrafiltration
OI ¼ oxygen index
PMN ¼ polymorphonuclear neutrophil
PVR ¼ pulmonary vascular resistance
RBC ¼ red blood cell
sICAM ¼ soluble intracellular adhesion molecule
SVR ¼ systemic vascular resistance
TNF ¼ tumor necrosis factor
TNFR ¼ tumor necrosis factor receptor
VO2 ¼ oxygen consumption
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Mcould indicate the intensity of activation of PMNs and endo-
thelial cells after CPB.8,9 In the present study, using
a randomized controlled trial design, we assessed the
safety of MUF and its associated inflammatory modulation
through tissue markers of inflammatory activity in adult
patients undergoing elective coronary artery bypass
grafting (CABG) with CPB support.
MATERIALS AND METHODS
Patient Selection
Approval for this study was obtained from the Institutional Review
Board for Human Research, and the trial was registered at Clinicaltrials.-
gov (Identifier: NCT01140113). Sixty consecutive patients undergoing
elective on-pump CABG were enrolled in the study. According to the
recommendations of the Declaration of Helsinki, all patients provided writ-
ten informed consent before enrollment. The Consolidated Standards of
Reporting Trials study flow is summarized in Figure 1.
Inclusion criteria were age between 30 and 70 years, left ventricle ejec-
tion fraction greater than 39%, and glomerular filtration rate (calculated by
the Cockcroft-Gault equation) greater than 45 mL/min/1.73 m2 in men or
greater than 40 mL/min/1.73 m2 in women. Exclusion criterion was indica-
tion for mitral valve repair or other surgical procedure in addition to the
planned CABG. All patients had discontinued aspirin or clopidogrel bisul-
fate therapy at 5 or 7 days, respectively, before the surgery.
Study Design
Patients were randomly assigned to the control group, which was treated
by CABG only, or the MUF group, which was treated by CABG plus MUF.
Neither the surgeon performing the operation nor the anesthesiologist in
charge was blinded to the nature of the experimental intervention. A
blinded nurse intensivist independently rated the chest tube blood loss
within the first 48 hours after surgery. A red blood cell (RBC) transfusion
was given in the intensive care unit (ICU) if the hemoglobin concentration
decreased to less than 9.0 g/dL at any time during hospitalization of the
patient.664 The Journal of Thoracic and Cardiovascular SurgBecause of a lack of previous studies using tissue inflammatory
markers, the sample size was calculated on the basis of chest tube blood
loss in the first 48 hours after surgery. A pilot study was carried out with
5 patients in each group. Sample size was calculated by using the software
G*Power with 80% power and an alpha error of 5%. The calculation pre-
dicted the need for 34 patients randomly divided into 2 arms to detect
a mean difference of 160.0  55.0 mL at 48 hours. An extra 13 patients
were added to each arm to improve study reliability.
Surgical Procedure
Anesthesia was induced with midazolam, atracurium besylate, and fen-
tanyl and was maintained with a balanced anesthesia of inhalant and intra-
venous agents. After anesthesia was induced, patients were monitored with
a continuous cardiac output catheter (Edwards Lifesciences, Irvine, Calif),
invasive arterial mean pressure catheter, and urine output catheter. A
planned tepid bypass (32C) was performed with a target flow of 2.4
L/min/m2. After CPB was established, the aorta was crossclamped and dis-
tal anastomoses were performed. Blood tepid cardioplegia was used during
the crossclamp period. The clamp was released, and a C-clampwas applied
for performance of the proximal anastomoses. Afterward, the patients were
weaned from the bypass. In all cases, the cardiotomy suction was used as
necessary.When needed to achieve optimal cardiac output, dopamine com-
bined with sodium nitroprusside was the preferred inotrope. All operations
were performed by 1 surgeon (O.P.).
Modified Ultrafiltration
MUFwas performed in heparinized patients between the arterial and ve-
nous tubing of the CPB circuit. An H-500 filter (polyethersulfone) was
used, which had an effective membrane area of 0.5 m2, pore size of
5 nm, prime volume of 34 mL, maximum transmembrane pressure of
400 mm Hg, internal fiber diameter of 200 mm, and fiber wall thickness
of 30 mm (Braile Biomedica, S~ao Jose do Rio Preto, Brazil). The blood
flow rate through the filter (300 mL/min) was maintained by a roller
pump on the inlet part of the filter. Suction was applied to the filtrate
port to achieve a negative pressure of 100 mm Hg. The process was carried
out for 15 minutes in all patients who underwent MUF. Patients assigned to
the control group were instead observed for 15 minutes.
Oxygen Transport and Hemodynamic Parameters
Blood was sampled, and the indexed cardiac output, systemic vascular
resistance (SVR), pulmonary vascular resistance (PVR), mean arterial
pressure, oxygen delivery (DO2), oxygen consumption (VO2), oxygen in-
dex (OI), and alveolar-arterial oxygen gradient (A-aDO2) were recorded
just after induction of anesthesia, before and after MUF, and at 24 and
48 hours after CABG. OI was calculated by OI ¼ (FIO2 3 MAP)/PaO2.
The A-aDO2 was calculated by A-aDO2¼ 7133 (FIO2 - PaO2 - PaCO2), where
FIO2 is the inspired fraction of oxygen, MAP is the mean airway pressure,
and PaO2 and PaCO2 are the partial pressures of oxygen and carbon dioxide,
respectively, in the arterial blood.
Blood samples were collected from the arterial line with heparin-coated
tubes. Collected samples were centrifuged for 20 minutes at 4C, and se-
rum aliquots were stored at80C. Levels of interleukin (IL)-6, P-selectin,
soluble intracellular adhesion molecule (sICAM) 1, and soluble tumor
necrosis factor receptor (TNFR) 2 were measured with commercially avail-
able enzyme-linked immunosorbent assay kits (R&D Systems, Abingdon,
UK). Serum creatinine, international normalized ratio (INR) for prothrom-
bin time, activated partial thromboplastin time, leukocyte count, serum
lactate, and blood urea nitrogen were measured after blood collection at
the hospital central laboratory.
Study Outcomes
Primary outcomes were chest tube blood loss within the first 48 hours
after surgery, blood transfusion requirement (rated as the number ofery c September 2012
FIGURE 1. Consolidated Standards of Reporting Trials flowchart of the study. MUF, Modified ultrafiltration.
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MRBC units transfused before hospital discharge), ICU length of stay (days),
and hospital length of stay (days). Secondary outcome was inflammatory
response, which was assessed by serum levels of IL-6, soluble TNFR2,
P-selectin, and sICAM-1.
Statistical Analyses
Continuous variables were expressed as means with 1 standard devia-
tion. Categoric variables were expressed as frequencies. All data were
tested for normality, and transformations were performed as necessary.
The t test for unpaired samples was used to analyze total bleeding volume
and required units of transfused RBCs. Two-way analysis of variance was
performed for intragroup, intergroup, and time/group interactions with the
Bonferroni post hoc test (GraphPad Prism version 5.0 for Mac OS X;
GraphPad Software Inc, San Diego, Calif).
RESULTS
Demographic Data and Intraoperative Variables
Demographic and surgical data were similar between
the 2 groups, although the control group showed a lower
incidence of peripheral arterial disease (P ¼ .03) (Table
1). Chest tube drainage was lower in the MUF group
(P ¼ .04), which also received fewer transfusions of RBC
units (P ¼ .03). No patient in either group required medias-
tinal reexploration for postoperative bleeding.
Hemodynamic Variables and Oxygen Transport
SVR index and DO2 decreased and VO2, OI, and
alveolar-arterial (A-a) gradient increased in both groups
during the observation period; however, there were no
differences between the MUF and control groups in these
parameters (Table 2).The Journal of Thoracic and CaHematocrit, Lactate, Blood Cell Count, and Blood
Clot Tests
Results of the hematocrit, lactate, blood cell counts, and
blood clot tests are summarized in Table 3. Hematocrit de-
creased during the observation period and was higher in the
MUF group, particularly immediately after the MUF proce-
dure (P ¼ .02). Lactate levels, leukocyte count, and INR
increased in both groups compared with measurements
taken immediately after anesthesia induction, but there
were no differences in these parameters between the control
and MUF groups.
Inflammatory Mediators
Serum IL-6 levels were elevated after induction of anesthe-
sia in both groups. The IL-6 levels were higher in the MUF
group right after ultrafiltration (P<.05) and comparable at
24 and 48 hours after surgery (Figure 2, A). The P-selectin
levels remained steady in both groups during the observation
period compared with baseline values (P ¼ .79), and no dif-
ferences were observed between the groups (Figure 2, B).
At the post-MUF time point, the sICAM-1 plasma levels
were increased in the MUF group and remained higher than
those of the control group up to 48 hours (P < .0001)
(Figure 3, A). The TNFR2 levels were higher in the MUF
group than in the control group at 48 hours (Figure 3, B).
DISCUSSION
The current study investigated the effects of MUF in
adult patients undergoing CABG with CPB support. Userdiovascular Surgery c Volume 144, Number 3 665
TABLE 1. Demographics, surgical data, postoperative bleeding,
intensive care unit and hospital lengths of stay, and number of red
blood cell units transfused per patient
Group (n ¼ 30 each) P
valueMUF Control
Gender (F/M) 20% (6/24) 7% (2/28) .13
Age (y) 55.2  7.3 55.6  9.3 .84
CPB time (min) 51  10 56  8 .06
Grafts per patient* 3 (3–3) 3 (3–4) .35
Hypertension 73% (22/8) 83% (25/5) .35
Previous cerebral stroke 3% (1/29) 7% (2/28) .55
DM 33% (10/20) 27% (8/22) .57
Smoker 90% (27/30) 90% (27/30) 1.00
Ejection fraction (%) 60  13% 62  8% .69
Peripheral arterial disease 0% (0/30) 20% (6/24) .03
Volume removal with MUF (mL) 995  160 0  0 <.01
Chest tube drainage (48 h) 645  163 846  399 .02
Fresh-frozen plasma (units) 0.1  0.6 0.2  0.8 .72
RBC (units) 0.7  0.7 1.5  1.3 .01
Length of stay in ICU (d) 3.4  0.3 3.5  0.3 .90
Length of stay in hospital (d) 5.1  0.5 4.9  0.5 .77
Statins 63% (19/30) 40% (12/30) .12
MUF, Modified ultrafiltration; F, female; M, male; CPB, cardiopulmonary bypass;
DM, diabetes mellitus; RBC, red blood cell; ICU, intensive care unit. *Median
(95% confidence interval).
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Mof MUF resulted in decreased postoperative blood loss, as
indicated by decreased chest tube blood drainage and fewer
RBC units transfused. Patients undergoing MUF presented
hemodynamic, oxygen transport, and pulmonary parame-
ters that were indistinguishable from those of the control
group. Lactate levels, leukocyte count, activated partial
thromboplastin time, and INR varied throughout the entire
observation period, but no differences were detected
between the 2 groups. Hematocrit was higher in the post-
MUF period compared with the control group, but similar
between the groups at 48 hours. Similar operative mortal-
ities and lengths of stay in the ICU and hospital were seen
in the 2 groups. Most of the inflammatory markers mea-
sured, such as soluble adhesion molecules and cytokines,
were increased in the MUF group compared with the con-
trol group for most of the observation period. Higher serum
sICAM and TNFR2 levels were seen in theMUF group than
in the control group, particularly in the post-MUF period.
These findings suggest that MUF is a relatively safe
procedure for removing fluids, increasing hematocrit, and
diminishing postoperative bleeding. However, MUF was
not effective for ameliorating the inflammatory response
or reducing the ICU and hospital lengths of stay after car-
diac surgeries using CPB in the present study.Postoperative Blood Loss and Hemodynamic
Parameters
The findings presented in this article are consistent with
results reported in the literature regarding the adult666 The Journal of Thoracic and Cardiovascular Surgpopulation after cardiac surgery using CPB with ultrafiltra-
tion. Several authors have reported decreased postoperative
bleeding after use of MUF.10,11 In a meta-analysis of 11
articles, Boodhwani and colleagues11 showed favorable
effects of ultrafiltration in reducing postoperative bleeding
in adult patients. Six of the 11 articles had used MUF alone
or in addition to conventional ultrafiltration. Kuratani and
colleagues12 performed a meta-analysis of ultrafiltration
use in the pediatric population. By focusing on hematocrit
and blood pressure after CPB, amount of chest tube drain-
age within 48 hours after surgery, time to extubation, and
length of stay in the ICU, they reported higher hematocrit
in the immediate postbypass period, but similar postopera-
tive outcome parameters in the MUF and control groups.
Likewise, we observed higher hematocrit levels at the end
of bypass (but no difference at 48 hours), lower chest tube
drainage within 48 hours of surgery, and no difference in
the length of stay in the ICU or hospital in the MUF group
compared with the control group.
In patients undergoing cardiac procedures with CPB and
using a blinded anesthetist and intensivist (but an unblinded
surgeon), Boodhwani and colleagues13 found that MUFwas
associated with an effective hemoconcentration and an in-
creased need for vasopressor support. They did not evaluate
blood chest tube drainage in the postoperative period. By
using a blinded intensivist, but unblinded surgeon and anes-
thetist, we observed an effective hemoconcentration imme-
diately after MUF, and patients receiving MUF required
fewer RBC transfusions. The hemodynamic parameters
were similar in the 2 groups.
Leyh and colleagues14 studied a small sample of patients
scheduled for elective myocardial revascularization who
were randomized to groups undergoing conventional ultra-
filtration, MUF, or no ultrafiltration. They obtained results
comparable to those of the present work, with reduced
blood loss at 24 hours after surgery in the MUF group com-
pared with the conventional ultrafiltration and no ultrafiltra-
tion groups, and similar results of routine clot tests among
all 3 groups.14 Leyh and colleagues could not elucidate
the mechanism(s) for reduced blood loss.
In a study of adult patients undergoing complex cardiac
surgery with or without MUF, Weber and colleagues15
assessed blood loss and performed routine clot tests,
multiple electrode aggregometry, and thromboelastome-
try. Multiple electrode aggregometry assesses general
platelet aggregation, and thromboelastometry investigates
intrinsic and extrinsic initiation of coagulation, plasmatic
contributors to clot firmness, and heparin effects. Weber
and colleagues found reduced postoperative blood loss
in the MUF group compared with control, but no differ-
ences between the groups for the results of routine clot
tests or thromboelastometry. However, platelet aggrega-
tion was improved in the MUF group compared with
the control, which may partially explain the reducedery c September 2012
TABLE 2. Hemodynamic variables and oxygen transport
Group (n ¼ 30 each) Induction of anesthesia Pre-MUF Post-MUF 24 h 48 h P* Py Pz
CI (L/min/m2) MUF 3.4  0.6 4.1  2.2 3.2  0.7 3.4  0.6 3.5  0.5 <.01 .07 .93
Control 3.2  0.5 3.1  1.3 3.7  1.3 3.2  0.5 3.7  0.8
SVRi (dine/s/cm5/m2) MUF 673.9  57.5 453.0  38.3 635.6  48.6 539.3  43.7 516.3  29.9 .52 <.01 .79
Control 694.9  58.6 551.3  58.9 514.3  50.5 595.4  46.6 524.8  37.6
PVRi (dine/s/cm5/m2) MUF 62.4  6.4 57.8  6.9 80.2  8.6 61.0  8.9 52.5  6.1 .08 .18 .73
Control 69.8  9.5 59.2  7.2 55.7  6.9 60.8  7.8 56.3  5.9
DO2 (mL/min/m
2) MUF 618  147 478  142 517.5  120 405  78 401  86 .04 <.01 .52
Control 580  101 418  175 550  175 367  63 435  115
VO2 (mL/min/m
2) MUF 120  48 109  46 100  31 153  29 159  35 .38 <.01 .09
Control 105  27 96  43 81  38 146  24 162  45
OE (%) MUF 0.19  0.01 0.25  0.02 0.20  0.01 0.39  0.02 0.40  0.02 .29 .01 .32
Control 0.19  0.01 0.24  0.02 0.15  0.01 0.40  0.02 0.38  0.02
OI MUF 0.40  0.03 0.60  0.06 0.43  0.05 0.60  0.06 0.59  0.06 .51 <.01 .43
Control 0.39  0.04 0.70  0.11 0.43  0.05 0.67  0.09 0.59  0.07
A-a difference MUF 172  24 342  19 278  18 124  21 121  18 .95 <.01 .77
Control 166  28 358  27 281  26 145  19 118  21
MUF, Modified ultrafiltration; CI, cardiac index; SVRi, systemic vascular resistance index; PVRi, pulmonary vascular resistance index; DO2, oxygen delivery; VO2, oxygen
uptake; OE, oxygen extraction; OI, oxygenation index; A-a, alveolar-arterial. *Interaction between group and time. yEffect over time. zIntergroup effect by 2-way analysis of
variance.
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Mpostoperative blood loss observed in their work and in the
current study.
Boga and colleagues16 studied adult patients undergoing
CABG with MUF performed 10 to 15 minutes after CPB.
Higher SVR, cardiac output, and PVR were observed at
the end of the surgery in the hemofiltered group. However,
after 48 hours, these parameters were decreased compared
with baseline, with no difference between the hemofiltered
and control groups. In the present study, similar SVR, CI,
and PVR results were seen in both groups at all time pe-
riods, and these values were decreased after 48 hours.
Because we used different time points than Boga and
colleagues to assess CI, PVR, cardiac output, and SVR,
it may not be possible to compare the results immediately
after MUF. However, at 20 hours after surgery, Boga andTABLE 3. Hematocrit, lactate, blood cell count, and blood clot tests
Group (n ¼ 30 each) Induction of anesthesia
Hematocrit (%) MUF 41.4  4.7
Control 41.7  3.7
Lactate (mmol/L) MUF 1.1  0.5
Control 1.2  0.2
Platelets (109/L) MUF 231.0  18.0
Control 211.5  1.4
Leucocytes (109/L) MUF 9.0  0.8
Control 10.6  1.8
Creatinine (mg/dL) MUF 0.98  0.03
Control 0.99  0.07
aPTT MUF 1.12  0.13
Control 1.16  0.15
INR for prothrombin time MUF 1.13  0.03
Control 1.16  0.04
MUF, Modified ultrafiltration; aPTT, activated partial thromboplastin time; INR, intern
zIntergroup effect by 2-way analysis of variance.
The Journal of Thoracic and Cacolleagues observed equivalent CI, SVR index, PVR in-
dex, DO2, and VO2 values in both groups, similar to our
findings.
By examining the relationship among DO2, VO2, and cy-
tokine secretion in a pediatric population with MUF, Li and
colleagues17 found a decrease in VO2 after CPB throughout
a 12-hour period, as well as a correlation between IL-8 and
tumor necrosis factor (TNF) levels. However, Li and col-
leagues did not use a control group. In the present study,
VO2 was increased in both groups, and there was no corre-
lation between cytokine secretion and VO2. Moreover,
MUF showed no deleterious or beneficial effects on VO2
or DO2 compared with the control. Although OI increased
during the observation period, no difference in this index
was seen between the groups.Pre-MUF Post-MUF 24 h 48 h P* Py Pz
31.5  4.0 37.9  4.8 28.8  3.1 28.5  3.1 .04 <.01 .31
31.8  4.1 34.3  4.7 28.3  4.7 28.4  2.7
2.9  1.3 2.7  1.3 2.5  1.1 2.3  0.6 .84 <.01 .50
2.8  1.5 2.6  1.5 3.1  1.0 2.4  1.2
149.9  10.9 102.1  9.1 .44 <.01 .66
145.2  1.1 105.9  5.7
19.8  1.3 19.8  2.9 .29 <.01 .79
16.7  1.3 19.9  1.7
1.09  0.10 0.90  0.20 .94 <.01 .91
1.12  0.08 0.87  0.08
1.14  0.12 1.18  0.31 .70 .44 .20
1.23  0.18 1.19  0.14
1.14  0.03 1.16  0.07 .13 <.01 .31
1.17  0.04 1.14  0.03
ational normalized ratio. *Interaction between group and time. yEffect over time.
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FIGURE 2. Plasma concentrations of (A) IL-6 and (B) P-selectin in the
control and MUF groups. Values represent means and standard errors of
the mean. *P<.05 by 2-way analysis of variance with Bonferroni multiple
comparisons post hoc test. IL, Interleukin; MUF, modified ultrafiltration.
FIGURE 3. Plasma concentrations of (A) sICAM-1 and (B) TNFR2 in the
control andMUF groups. Values represent means and standard errors of the
mean. *P<.01 and **P<.001 by 2-way analysis of variance with Bonfer-
roni multiple comparison post hoc test. MUF, Modified ultrafiltration;
TNFR2, tumor necrosis factor receptor 2; sICAM-1, soluble intracellular
adhesion molecule 1.
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MBy usingMUF and control groups, Chew and colleagues4
performed a randomized prospective study of pediatric pa-
tients. They observed a slight improvement in OI, but no
differences in mechanical ventilation time or A-a gradient,
in the MUF group. Our findings for the A-a gradient were
similar to those of Chew and colleagues, initially increasing
after surgery before returning to baseline values at 48 hours.
No differences were seen between the MUF and control
groups.4
Effect of Ultrafiltration on Levels of Plasma
Inflammatory Mediators
Most studies of MUF use in adults have estimated the in-
flammatory response through plasma levels of mediators,
such as TNF and IL-6. TNF may play an important role in
inflammation after cardiac surgery by binding to its recep-
tors, TNFR1 or TNFR2, the latter of which is associated
with cardiac and renal functional impairment in patients
with coronary artery disease.18 Similar serum expression668 The Journal of Thoracic and Cardiovascular Surglevels of TNF are found in patients with heart failure with
reduced or preserved ejection fraction. Increased serum
TNFR2 expression in patients with heart failure and pre-
served ejection fraction is associated with a poor prognosis
and heart failure progression.19 However, serum expression
levels of TNF and IL-6 may not reflect the tissue inflamma-
tory response, and their use may explain the observed con-
tradictions between studies.6
Activation of PMNs and endothelial cells, which play
prominent roles in the inflammatory response after
CPB,20 initiates a cascade of cell-cell interactions that am-
plify the inflammatory response. These interactions require
the expression of specific adhesion proteins on the cell sur-
face, which include well-known markers of cell activation,
such as soluble L-selectin (expressed by neutrophils),ery c September 2012
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MP-selectin (expressed by platelets and endothelial cells),7
and intracellular adhesion molecule (ICAM) 1. Selectin
proteins establish a first step in the cascade of immunologic
interactions between endothelial and immunocompetent
cells, mediating the initial adhesion and rolling of leuko-
cytes on endothelial surfaces.7 Although increased plasma
levels of P-selectin are unlikely to indicate platelet dysfunc-
tion, it remains unclear whether they reflect endothelial dys-
function or platelet activation.7 An immunoglobulin gene
superfamily member, ICAM-1 mediates leukocyte adhesion
and transmigration through the endothelium. Elevated
ICAM-1 levels are found in tissues affected with malignan-
cies, inflammatorydiseases, and ischemia.21After proteolytic
cleavage of the ICAM-1 molecule, soluble ectodomain is re-
leased from the cell surface and may modulate inflammation
by binding to leukocyte integrins.21
In several reports, MUF has been shown to improve clin-
ical function by removing inflammatory mediators, such as
the cytokines and soluble adhesion molecules.6 However, it
is not known whether a reduction in inflammatory media-
tors actually reduces the patient inflammatory process after
CPB or whether any type of ultrafiltration is capable of ame-
liorating the inflammatory response after CPB. By applying
a similar filter as used in the present study, we previously
showed that the efficient removal of inflammatory media-
tors from conventionally hemofiltered fluid had no clear
clinical benefit when performed during CABG in adults.22
Tallman and colleagues23 found that use of zero-balance ul-
trafiltration in patients undergoing CABG had no clear clin-
ical benefit, although it was capable of removing significant
amounts of proinflammatory mediators (eg, IL-6, IL-1, and
TNF). These findings are similar to those of the present
study in terms of clinical variables, such as ICU and hospital
lengths of stay.
Weobserved higher serum levels of IL-6 immediately after
MUF compared with the control group. However, at 24 and
48 hours, the IL-6 levels were comparable between groups,
as reported by others.6,22,24 Although we observed an
increase in TNFR2 expression in the MUF group, which
may indicate a worsening of the inflammatory response, we
did not observe any negative clinical outcome (ie, renal or
cardiac dysfunction) related to this finding. Unfortunately,
we cannot explain the biological importance of this
observation. Steady P-selectin levels were seen throughout
the observation period in both groups, suggesting that MUF
adds little further injury to the platelets in addition to what
has occurred as a result of bypass. The observed constant
P-selectin level might corroborate the improvement of
platelet aggregation after MUF reported by Weber and
colleagues.15
Grunenfelder and colleagues6 compared patients under-
going normothermic or hypothermic CPB with MUF.
They found decreased ICAM and E-selectin levels after
MUF, particularly after hypothermic CPB. In the presentThe Journal of Thoracic and Castudy, all patients underwent normothermic CPB, and the
hemofilter used was similar to that used by Grunenfelder
and colleagues, although with a higher surface area (0.5
vs 0.2 m2). We observed that serum ICAM expression
was higher in the MUF group than in the control group.
The MUF group experienced more blood contact with for-
eign structures, such as nonendothelial surfaces and hemo-
filter fibers. The increased contact may have increased
endothelial activation, as described in patients using left
ventricular assist devices,25 which was evidenced by the
elevated ICAM serum levels. Despite such differences in
the ICAM serum levels, the clinical variables were similar
between the groups and to those of Grunenfelder and col-
leagues6 after MUF.
Overall, the results of the current study and previous
studies suggest that removal of inflammatory mediators
with any type of hemofiltration does not necessarily reduce
all inflammation in a patient after CPB. In this regard, other
strategies for reducing the inflammatory response after
CPB, such as through the use of statins and angiotensin-
converting enzyme inhibitors, may be more efficient than
hemofiltration.1
Study Limitations
Our study was limited by the sample size, although we
were able to show a significant decrease in postoperative
bleeding and an increase in ICAM and TNFR2 serum levels
after MUF.
The surgeon and anesthesiologist were not blinded for
group selection, but all measurements (ie, chest tube drain-
age, inflammatory markers, hematocrit, transfusion deci-
sions) were performed in a blinded manner. The study
was not designed to evaluate mortality, ICU stay, or hospital
length of stay.
We did not measure the inflammatory mediators in the
removed hemofiltered fluid. However, the pore size, trans-
membrane pressure, and filter area used should be suffi-
cient for the efficient removal of inflammatory mediators,
according to previous studies.6,24
CONCLUSIONS
MUF is a safe procedure for intraoperative fluid manage-
ment that is able to reduce postoperative bleeding and the
need for RBC transfusion. However, MUF is not capable
of reducing the inflammatory response and shows no clini-
cal beneficial effects after CPB in adult patients undergoing
CABG.
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